# Mechanisms and Therapeutic Potential of Human Cardiomyocyte Proliferation

**Authors:** Richard D. McLane, Abhay Cheruku, Ashley B. Williams, Ravi Karra

PMC · DOI: 10.3390/jcdd13020074 · 2026-02-02

## TL;DR

This paper explores how to stimulate heart muscle cell growth in humans to improve recovery from heart injury.

## Contribution

The paper reviews mechanisms and translational challenges of promoting cardiomyocyte proliferation for heart regeneration.

## Key findings

- Reactivating cardiomyocyte proliferation could aid heart regeneration in humans.
- Pre-clinical success has led to early-phase clinical trials.
- Translational challenges include delivery methods and safety concerns.

## Abstract

The limited capacity for cardiomyocyte proliferation in the adult human heart restricts its ability to recover from injury. Building on discoveries in regenerative model systems, such as zebrafish and neonatal mice, reactivation of a latent potential for cardiomyocyte proliferation is a strategy to promote therapeutic heart regeneration. Although cardiomyocyte proliferation remains modest even with the most effective mitogenic stimuli identified to date, evidence for a potential functional benefit in pre-clinical model systems has led to the initiation of several early-phase clinical programs. Here, we review insights from model organisms that inform the potential efficacy and limitations of therapeutic cardiomyocyte proliferation, systems to study human cardiomyocyte proliferation, and the natural history of cardiomyocyte proliferation in the human heart. We also examine the translational trajectory of selected discoveries, including therapeutic delivery modalities, and attendant safety concerns. Finally, we discuss critical challenges that will need to be addressed to enable successful clinical translation.

## Linked entities

- **Species:** Danio rerio (taxon 7955), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Sav1 (salvador family WW domain containing 1) [NCBI Gene 64010] {aka 1700040G09Rik, Salv, Sav, WW45, Wwp3, Wwp4}, MIR208A (microRNA 208a) [NCBI Gene 406990] {aka MIR208, MIRN208, MIRN208A, hsa-mir-208a, miRNA208}, Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, Gata4 (GATA binding protein 4) [NCBI Gene 14463] {aka Gata-4}, Nrg1 (neuregulin 1) [NCBI Gene 211323] {aka 6030402G23Rik, ARIA, D230005F13Rik, GGF, GGFII, HRG}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, ERBB3 (erb-b2 receptor tyrosine kinase 3) [NCBI Gene 2065] {aka ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Agrn (agrin) [NCBI Gene 11603] {aka Agrin, nmf380}, Erbb2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 13866] {aka Erbb-2, HER-2, HER2, Neu, c-erbB2, c-neu}, Myh7 (myosin, heavy polypeptide 7, cardiac muscle, beta) [NCBI Gene 140781] {aka B-MHC, MYH-beta/slow, MyHC-I, Myhc-b, Myhcb, beta-MHC}, Cdk4 (cyclin dependent kinase 4) [NCBI Gene 12567] {aka Crk3}, Myh6 (myosin, heavy polypeptide 6, cardiac muscle, alpha) [NCBI Gene 17888] {aka A830009F23Rik, Myhc-a, Myhca, alpha-MHC, alphaMHC}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, Cpt1b (carnitine palmitoyltransferase 1b, muscle) [NCBI Gene 12895] {aka Cpt1, Cpt1-m, Cpti, Cpti-m, M-cpti}, Cdk1 (cyclin dependent kinase 1) [NCBI Gene 12534] {aka Cdc2, Cdc2a, p34<CDC2>}, Dyrk1a (dual-specificity tyrosine phosphorylation regulated kinase 1a) [NCBI Gene 13548] {aka 2310043O08Rik, D16Ertd272e, D16Ertd493e, Dyrk, Gm10783, Mnbh}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ISL1 (ISL LIM homeobox 1) [NCBI Gene 3670] {aka ISLET1, Isl-1}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Ccna2 (cyclin A2) [NCBI Gene 12428] {aka Ccn-1, Ccn1, Ccna, CycA2, Cyca}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, Dmd (dystrophin, muscular dystrophy) [NCBI Gene 13405] {aka DXSmh7, DXSmh9, Dp427, Dp71, dys, mdx}, ITIH3 (inter-alpha-trypsin inhibitor heavy chain 3) [NCBI Gene 3699] {aka H3P, ITI-HC3, SHAP}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Erbb4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 13869] {aka Her4, c-erbB-4}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, KIF23 (kinesin family member 23) [NCBI Gene 9493] {aka CDA3, CDAIII, CDAN3, CDAN3A, CHO1, KNSL5}, NRG1 (neuregulin 1) [NCBI Gene 3084] {aka ARIA, GGF, GGF2, HGL, HRG, HRG1}, Ccnb1 (cyclin B1) [NCBI Gene 268697] {aka Ccnb1-rs1, Ccnb1-rs13, CycB1, Cycb-4, Cycb-5, Cycb1-rs1}, Aurkb (aurora kinase B) [NCBI Gene 20877] {aka AIM-1, AIRK2, Aik2, Aim1, Ark2, AurB}, Egf (epidermal growth factor) [NCBI Gene 13645]
- **Diseases:** EHTs (MESH:D006331), cardiomegaly (MESH:D006332), hypertrophic cardiomyopathy (MESH:D002312), cardiac remodeling (MESH:D020257), Heart failure (MESH:D006333), infarct (MESH:D007238), breast cancer (MESH:D001943), hypoplastic hearts (MESH:D018636), ventricular fibrillation (MESH:D014693), death (MESH:D003643), coronary thrombus (MESH:D013927), embryonic lethality (MESH:D020964), congenital heart disease (MESH:D006330), toxicities (MESH:D064420), thickened (MESH:D013585), atrial fibrillation (MESH:D001281), myocardial ischemia (MESH:D017202), end-stage heart failure (MESH:D007676), hypertrophy (MESH:D006984), myocardial infarction (MESH:D009203), sudden death (MESH:D003645), dilated cardiomyopathies (MESH:D002311), stroke (MESH:D020521), tumorigenesis (MESH:D063646), sudden cardiac death (MESH:D016757), cardiomyopathy (MESH:D009202), arrhythmia (MESH:D001145), bleeding (MESH:D006470), left ventricular dysfunction (MESH:D018487), arrhythmic (OMIM:212500), cardiotoxicity (MESH:D066126), ischemia (MESH:D007511), Tetralogy of Fallot (MESH:D013771), fibrosis (MESH:D005355), injury to (MESH:D014947), ischemic (MESH:D002545), cancer (MESH:D009369), right ventricular failure (MESH:D051437)
- **Chemicals:** palmitic acid (MESH:D019308), Lipid (MESH:D008055), amiodarone (MESH:D000638), calcium (MESH:D002118), HEQ-001 (-), propranolol (MESH:D011433), pseudouridine (MESH:D011560), ivabradine (MESH:D000077550), EdU (MESH:C022811), uridine (MESH:D014529), mevalonate (MESH:D008798), 14C (MESH:C000615234), trastuzumab (MESH:D000068878), glycan (MESH:D011134)
- **Species:** Gallus gallus (bantam, species) [taxon 9031], Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Sus scrofa (pig, species) [taxon 9823], Adeno-associated virus (species) [taxon 272636], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** AC16 — Homo sapiens (Human), Transformed cell line (CVCL_HA69)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941982/full.md

---
Source: https://tomesphere.com/paper/PMC12941982